Lupin Launches Emergency Glucagon Kit in US for Severe Hypoglycemia

Lupin, a leading player in branded, generic formulations, and APIs, has introduced an emergency kit for treating severe low blood sugar in the US. According to IQVIA data, the drug category sees annual sales of about $122 million in the US. The company’s shares rose after the announcement.

The new product, Glucagon for Injection USP (1 mg/vial), is packaged in an emergency kit and is a bioequivalent to Eli Lilly’s formulation. Glucagon is used to treat severe hypoglycemia in both children and adults with diabetes and serves as a diagnostic aid in gastrointestinal imaging for adults.

Lupin aims to expand its injectables and biosimilars portfolio, leveraging R&D and manufacturing strengths. The company expects significant growth in 2025 with launches including Glucagon, Liraglutide, and Risperdal Consta. With the USFDA easing regulations for emerging biologics and private labels, Lupin is advancing its 30-product injectables pipeline alongside biosimilars and inhalation therapies.